Who are Restylane-L® Lyft's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hyaluronic acid filler/IMD1 basic, Belotero Balance, HA filler, Emervel® Touch, Radiesse, Xeomin, Belotero, Restalyne Silk.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/restylane-l-lyft.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Restylane-L® Lyft — Competitive Intelligence Brief

Restylane-L® Lyft (Restylane-L® Lyft) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dermal filler. Area: Dermatology / Aesthetics.

marketed Dermal filler Dermatology / Aesthetics Small molecule Live · refreshed every 30 min

Target snapshot

Restylane-L® Lyft (Restylane-L® Lyft) — University of Pennsylvania. Restylane-L Lyft is a hyaluronic acid-based dermal filler that adds volume and structure to facial tissues to correct moderate to severe facial folds and wrinkles.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Restylane-L® Lyft TARGET	Restylane-L® Lyft	University of Pennsylvania	marketed	Dermal filler
Hyaluronic acid filler/IMD1 basic	Hyaluronic acid filler/IMD1 basic	Merz Pharmaceuticals GmbH	marketed	Dermal filler
Belotero Balance	Belotero Balance	The Maas Clinic	marketed	Dermal filler	Hyaluronic acid receptor (CD44)
HA filler	HA filler	University of Pennsylvania	marketed	Dermal filler
Emervel® Touch	Emervel® Touch	Hexsel Dermatology Clinic	marketed	Dermal filler	Hyaluronic acid receptor (CD44)
Radiesse, Xeomin, Belotero	Radiesse, Xeomin, Belotero	Main Line Center for Laser Surgery	marketed	Dermal fillers and neurotoxin
Restalyne Silk	Restalyne Silk	The Maas Clinic	marketed	Dermal filler	Hyaluronic acid receptor (CD44)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dermal filler class)

The Maas Clinic · 2 drugs in this class
University of Pennsylvania · 2 drugs in this class
Hexsel Dermatology Clinic · 1 drug in this class
Merz Pharmaceuticals GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Restylane-L® Lyft — Competitive Intelligence Brief. https://druglandscape.com/ci/restylane-l-lyft. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab